Featured Research

from universities, journals, and other organizations

Prevention Of Prostate Cancer, Osteoporosis In Men Under Study

October 28, 2004
Medical College Of Georgia
Preventing prostate cancer and helping men with the disease avoid osteoporosis is the focus of two new clinical trials at the Medical College of Georgia.

Dr. James A. Brown, Medical College of Georgia urologist specializing in prostate cancer, and Mary Anne Park, director of the MCG Surgical Research Service, are looking at treatments to prevent prostate cancer and prevent osteoporosis in men who have the disease.
Credit: Photo courtesy of Medical College Of Georgia

Preventing prostate cancer and helping men with the disease avoid osteoporosis is the focus of two new clinical trials at the Medical College of Georgia.

MCG is participating in a national study to determine whether men can reduce their prostate cancer risk by taking a drug that halts the conversion of the male hormone to a super-duper hormone that appears to stimulate prostate cancer growth.

The lifetime risk of prostate cancer is about 1 in 6 for American men, except for blacks as well as men with a family history who are at increased risk, according to the National Prostate Cancer Coalition; the risk increases to about 50 percent by age 80.

MCG also is a study site for a national study looking at whether a new drug that slows bone resorption can help prostate cancer patients avoid osteoporosis.

The cancer prevention study examines the potential of dutasteride, the active ingredient in a drug marketed to treat prostate enlargement, a common problem of aging.

“While there is no direct relationship between prostate enlargement and prostate cancer, both cancerous and benign growth of the prostate appear to be stimulated by this super hormone called dihydrotestosterone,” says Dr. James A. Brown, MCG urologist specializing in prostate cancer. For some unknown reason, circulating male hormone, testosterone, is converted into this more potent male hormone in the prostate gland and scalp. “What is neat about that is if you can prevent that conversion … you are taking away a potent stimulator of cell growth,” says the Georgia Cancer Coalition Distinguished Cancer Clinician and Scientist. “Many of the cells in the gland will atrophy and shrink away.”

For the prevention study, MCG is evaluating patients age 50-75 with elevated PSAs, a marker for prostate cancer, who have had a negative biopsy in the last six months. The study runs for four years and participants will receive additional biopsies at years two and four.

The osteoporosis prevention study looks at the bone-thinning disease often associated with menopausal women. Loss of the female hormone, estrogen, helps disrupt the normal balance between cells called osteoblasts that make bone and osteoclasts that consume it. While men also naturally experience a decline in their testosterone level with age, they keep making the hormone throughout life and tend to start out with denser bones than women, unless they get prostate cancer. Much like breast cancer, prostate cancer is a hormone-dependent cancer and a mainstay of treatment is hormone therapy. “Testicles make male hormone,” says Dr. Brown. “The prostate gland is a sex organ that responds to male hormone. This gland develops at puberty, with the influx of hormones, but it will often continue to grow throughout life, which is why sometimes with age, men have problems with an enlarged prostate. Cancer also will grow more rapidly and aggressively with male hormone circulating.”

Men often prefer that the testicles that produce male hormones not be surgically removed. The alternative is therapy that suppresses hormone production, essentially chemical castration to prevent signaling the testes to make hormone. “The mainstay of prostate cancer therapy is anti-hormone therapy and men typically are on it for years,” says Dr. Brown. Side effects often include markedly reduced libido as well as the increased risk of osteoporosis.

The study looks as a new bisphosphonate that slows bone resorption and may help correct the bone deficit that occurs with anti-hormone therapy, Dr. Brown says. For the study, MCG is looking for men with prostate cancer who are taking anti-hormone therapy for their disease. Participants will be followed for two years; half will receive the study drug and half will receive placebo. MCG expects to enroll about 20 patients in the study that will follow 1,200 men nationally.

Dr. Brown notes that in addition to new therapies still under evaluation, new treatment approaches already being used, such as laparoscopic and robotic surgery, are reducing the trauma and side effects of surgically removing a diseased prostate. The standard approach to removal has been about a six-inch vertical incision from the navel downward. Side effects include lost ability for a spontaneous erection and prolonged problems with incontinence. With five small incisions instead of one big one, the laparoscopic approach cuts post-surgical pain and recovery time. Less nerve damage also means men often regain continence more quickly and the minimally invasive approach appears to reduce the risk of ongoing erectile dysfunction, Dr. Brown says.

Story Source:

The above story is based on materials provided by Medical College Of Georgia. Note: Materials may be edited for content and length.

Cite This Page:

Medical College Of Georgia. "Prevention Of Prostate Cancer, Osteoporosis In Men Under Study." ScienceDaily. ScienceDaily, 28 October 2004. <www.sciencedaily.com/releases/2004/10/041027114135.htm>.
Medical College Of Georgia. (2004, October 28). Prevention Of Prostate Cancer, Osteoporosis In Men Under Study. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2004/10/041027114135.htm
Medical College Of Georgia. "Prevention Of Prostate Cancer, Osteoporosis In Men Under Study." ScienceDaily. www.sciencedaily.com/releases/2004/10/041027114135.htm (accessed July 30, 2014).

Share This

More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins